PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20542986-1	2010	PURPOSE: This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL).	ibritumomab tiuxetan	90-110	DNA damage inducible transcript 3	Homo sapiens	208-212	
20542986-5	2010	Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration.	ibritumomab tiuxetan	128-139	DNA damage inducible transcript 3	Homo sapiens	79-83	
25395425-0	2015	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.	ibritumomab tiuxetan	0-11	DNA damage inducible transcript 3	Homo sapiens	44-48